TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07822399: A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors

Sponsor: MacroGenics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 314 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07822399 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07822399 Rescue Dossier →